Cancer Treat Rep. 1985 Apr;69(4):417-20.
One hundred and five patients with advanced measurable pancreatic carcinoma were randomized to receive therapy with maytansine, low-dose chlorozotocin (120 mg/m2), or high-dose chlorozotocin (175 mg/m2). Objective response rates were as follows: maytansine, no responses among 48 patients; low-dose chlorozotocin, none among 27; and high-dose chlorozotocin, three among 30 (10%). Among patients with excellent performance status (Eastern Cooperative Oncology Group grade of 0-1) and no prior chemotherapy, response rates were as follows: maytansine, no responses among 17 patients; low-dose chlorozotocin, none among 14; and high-dose chlorozotocin, three among 28 (11%). The responses observed with high-dose chlorozotocin were transient (5-8 weeks) and were of no benefit to the patients. None of these agents given by the methods of this study can be recommended for patients with advanced pancreatic cancer.
105例晚期可测量胰腺癌患者被随机分为接受美登素、低剂量氯脲霉素（120mg/m²）或高剂量氯脲霉素（175mg/m²）治疗。客观缓解率如下：美登素组，48例患者中无缓解；低剂量氯脲霉素组，27例中无缓解；高剂量氯脲霉素组，30例中有3例缓解（10%）。在体能状态良好（东部肿瘤协作组0 - 1级）且未接受过化疗的患者中，缓解率如下：美登素组，17例患者中无缓解；低剂量氯脲霉素组，14例中无缓解；高剂量氯脲霉素组，28例中有3例缓解（11%）。高剂量氯脲霉素观察到的缓解是短暂的（5 - 8周），对患者并无益处。本研究采用的这些治疗方法均不推荐用于晚期胰腺癌患者。
